Drug Search Results
More Filters [+]

Prednisone

Alternative Names: prednisone, decortin, prednison, lodotra, apo-prednisone, rayos, CORTANCYL, orasone, prednisona, deltasone, cortan, liquid pred, delta-dome, meticorten, paracort, fernisone, servisone, prednicen-m, deltasone 5mg, prednimustine
Latest Update: 2024-06-14
Latest Update Note: Clinical Trial Update

Product Description

Prednisone is a synthetic, anti-inflammatory glucocorticoid that derives from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30521230/)

Mechanisms of Action: GR Agonist,Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Intestinal Diseases | Renal Transplant | Transplantation Unspecified | Kidney Diseases

Known Adverse Events: Weight Gain

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Prednisone

Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Asthma|Bronchiolitis Obliterans|Diffuse Large B-Cell Lymphoma|Drug Hypersensitivity|Erythema Multiforme|Giant Cell Arteritis|Graft vs Host Disease|Hepatic Insufficiency|Histiocytosis|Hodgkin Lymphoma|Kidney Diseases|Kidney Failure, Chronic|Liver Transplant|Lupus Nephritis|Lymphoid Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Nephrosis, Lipoid|Nephrotic Syndrome|Other|Pemphigoid, Bullous|Polymyalgia Rheumatica|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer|Renal Transplant|T-Cell Peripheral Lymphoma

Phase 2: Allogeneic Stem Cell Transplant|COVID-19|Depressive Disorder, Major|Fetal Diseases|GM1 Gangliosidosis|Gangliosidoses|Gangliosidosis, GM1|Granulomatosis with Polyangiitis|Heart Transplant|Kidney Transplant|Lung Cancer|Lung Transplant|Microscopic Polyangiitis|Nose Cancer|Pneumonia|Pregnancy Complications, Infectious|Pregnancy Outcomes|Radiation Pneumonitis|Systemic Vasculitis

Phase 1: Acute Myeloid Leukemia|B-Cell Leukemia|Blast Crisis|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CRESCENDO

P3

Recruiting

T-Cell Peripheral Lymphoma

2030-07-01

SHR6390-305

P1

Not yet recruiting

Prostate Cancer

2028-12-01

39%

SHR6390-305

P1

Not yet recruiting

Prostate Cancer

2028-12-01

39%

ROCKnrol-1

P3

Recruiting

Bronchiolitis Obliterans|Graft vs Host Disease

2028-09-29

86%

ROCKnrol-1

P3

Recruiting

Bronchiolitis Obliterans|Graft vs Host Disease

2028-09-29

86%

ROCKnrol-1

P3

Recruiting

Bronchiolitis Obliterans|Graft vs Host Disease

2028-09-29

86%

OLYMPIA-3

P3

Recruiting

Diffuse Large B-Cell Lymphoma

2028-09-18

41%

OLYMPIA-3

P3

Recruiting

Diffuse Large B-Cell Lymphoma

2028-09-18

41%

Recent News Events